Evidence map›Paper›PMID 38197376›Full record

ArticleNanomedicine (London, England)2023

Phospholipids impact the protective effects of HDL-mimetic nanodiscs against lipopolysaccharide-induced inflammation.

Sang Yeop Kim, Jukyung Kang, Maria V Fawaz, Minzhi Yu, Ziyun Xia, Emily E Morin, Ling Mei, Karl Olsen, Xiang-An Li, Anna Schwendeman

Open access · greenAbstract read
In one paragraph

Article in Nanomedicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sang Yeop KimDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-5781-9039
Jukyung KangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-2592-9401
Maria V FawazBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-4743-1444
Minzhi YuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-3141-7285
Ziyun XiaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-6409-1517
Emily E MorinDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0001-5253-2074
Ling MeiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-2762-2235
Karl OlsenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.
Xiang-An LiDepartment of Physiology, Saha Cardiovascular Research Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA.ORCID 0000-0002-6899-7332
Anna SchwendemanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48105, USA.ORCID 0000-0002-8023-8080
University of Michigan · USUniversity of Kentucky · US

Funding

INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2M
Cellular Biotechnology Training Program (CBTP)T32GM008353 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, ANNA · 1991 to 2021
$9.3M
Synthetic HDL_a potential sepsis therapyR01GM113832 · NIGMS · UNIVERSITY OF KENTUCKY · PI LI, XIANG-AN, SCHWENDEMAN, ANNA · 2015 to 2019
$3.0M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Training Program in Translational Cardiovascular Research and EntrepreneurshipT32HL125242 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MICHELE, DANIEL E · 2015 to 2024
$1.9M
Relative adrenal insufficiency as a risk factor and an endotype for sepsisR35GM141478 · NIGMS · UNIVERSITY OF KENTUCKY · PI LI, XIANG-AN · 2021 to 2025
$1.9M
Mechanism of adrenal insufficiency as a risk factor for sepsisR01GM121796 · NIGMS · UNIVERSITY OF KENTUCKY · PI LI, XIANG-AN · 2017 to 2020
$1.2M
BLRD VA I01 BX004639NHLBI NIH HHS T32 HL125242NIGMS NIH HHS R01 GM113832NIGMS NIH HHS R01 GM121796NIGMS NIH HHS R35 GM141478NIGMS NIH HHS T32 GM007767NIGMS NIH HHS T32 GM008353NIGMS NIH HHS T32 GM145304NIH HHS R01GM113832, R01GM121796, T32 GM007767, T32 GM008353, T32 HL125242
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LipopolysaccharidesPhospholipidsAnimalsAnti-Inflammatory AgentsDimyristoylphosphatidylcholineInflammationLipoproteins, HDLAnti-Inflammatory AgentsDimyristoylphosphatidylcholineLipopolysaccharidesLipoproteins, HDLPhospholipidsendotoxemiahigh-density lipoproteinsnanodiscsphospholipidssepsis

Identifiers

PMID38197376
PMCPMC10918510
OpenAlexW4390696186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.